These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 781711)

  • 1. The modification of the ethanol withdrawal syndrome in rats by di-n-propylacetate.
    Noble EP; Gillies R; Vigran R; Mandel P
    Psychopharmacologia; 1976 Mar; 46(2):127-31. PubMed ID: 781711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of di-n-propylacetate on the 'binding of GABA to synaptosome-enriched fraction of rat cerebral cortex.
    Kulig BM; Gonzalez-Portal C; Somoza E; Defeudis FV
    Psychopharmacology (Berl); 1977 Aug; 53(3):255-7. PubMed ID: 408853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticonvulsant action of ethanolamine-O-sulphate and di-n-propylacetate and the metabolism of gamma-aminobutyric acid (GABA) in mice with audiogenic seizures.
    Anlezark G; Horton RW; Meldrium BS; Sawaya CB
    Biochem Pharmacol; 1976 Feb; 25(4):413-7. PubMed ID: 779794
    [No Abstract]   [Full Text] [Related]  

  • 4. [On the mechanism of action of valproid acid].
    Löscher W; Frey HH
    Arzneimittelforschung; 1977; 27(5):1081-2. PubMed ID: 328017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A dual role for GABA in quasi-morphine abstinence behavior induced by di-n-propylacetate involving both initiation and termination.
    Van der Laan JW; Bruinvels J
    Psychopharmacology (Berl); 1981; 74(2):143-8. PubMed ID: 6791219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoamine and GABA metabolism and the anticonvulsant action of di-n-propylacetate and ethanolamine-O-sulphate.
    Horton RW; Anlezark GM; Sawaya MC; Meldrum BS
    Eur J Pharmacol; 1977 Feb; 41(4):387-97. PubMed ID: 139317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Di-n-propylacetate-induced abstinence behaviour as a possible correlate of increased GABA-ergic activity in the rat.
    de Boer T; Bartels K; Metselaar HJ; Bruinvels J
    Psychopharmacology (Berl); 1980; 71(3):257-67. PubMed ID: 6779333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticonvulsant and antiaggressive properties of di-n-propyl acetate after repeated treatment.
    Simler S; Ciesielski L; Klein M; Mandel P
    Neuropharmacology; 1982 Feb; 21(2):133-40. PubMed ID: 6801539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute functional tolerance to the motor impairment effects of di-n-propylacetate.
    Kulig BM
    Pharmacol Biochem Behav; 1976 Nov; 5(5):511-4. PubMed ID: 798205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of GABA-induced abstinence behaviour in naive rats by morphine and bicuculline.
    de Boer T; Metselaar HJ; Bruinvels J
    Life Sci; 1977 Mar; 20(6):933-41. PubMed ID: 191711
    [No Abstract]   [Full Text] [Related]  

  • 11. Differential effects of gamma-aminobutyric acid (GABA)-elevating agents on the neuroleptic-induced activation of striatal tyrosine-hydroxylase: evidence that di-n-propylacetate augments GABAergic neurotransmission.
    Casu M; Gale K
    J Pharmacol Exp Ther; 1981 Apr; 217(1):177-80. PubMed ID: 6110774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential sensitivity of ethanol withdrawal signs in the rat to gamma-aminobutyric acid (GABA)mimetics: blockade of audiogenic seizures but not forelimb tremors.
    Frye GD; McCown TJ; Breese GR
    J Pharmacol Exp Ther; 1983 Sep; 226(3):720-5. PubMed ID: 6310080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression by progabide of ethanol withdrawal syndrome in rats.
    Fadda F; Mosca E; Meloni R; Gessa GL
    Eur J Pharmacol; 1985 Mar; 109(3):321-5. PubMed ID: 2985405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gamma-aminobutyric acid (GABA) and sleep. The influence of di-n-propylacetic acid on sleep in man.
    Schneider E; Ziegler B; Maxion H
    Eur Neurol; 1977; 15(3):146-52. PubMed ID: 192556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quasi-morphine withdrawal behaviour: indication for a specific involvement of the GABA-ergic nerve terminal compartment.
    van der Laan JW
    Life Sci; 1983; 33 Suppl 1():389-92. PubMed ID: 6420629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions of di-n-propylacetate, gabaculine, and aminooxyacetic acid: anticonvulsant activity and the gamma-aminobutyrate system.
    Wood JD; Kurylo E; Tsui SK
    J Neurochem; 1981 Dec; 37(6):1440-7. PubMed ID: 6801201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proceedings: gamma-Aminobutyric acid metabolism and the anticonvulsant action of ethanolamine-o-sulphate and di-n-propylacetate.
    Anlezark GM; Horton RW; Meldrum BS; Sawaya MC; Stephenson JD
    Br J Pharmacol; 1976 Mar; 56(3):383P-384P. PubMed ID: 769882
    [No Abstract]   [Full Text] [Related]  

  • 18. Anticonvulsant activity of di-n-propylacetate and brain monoamine metabolism in the rat.
    Abed WT
    Clin Exp Pharmacol Physiol; 1990 Jan; 17(1):11-6. PubMed ID: 1693553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of chronic treatment with amino-oxyacetic acid or sodium n-dipropylacetate on brain GABA levels and the development and regression of cobalt epileptic foci in rats.
    Emson PC
    J Neurochem; 1976 Dec; 27(6):1489-94. PubMed ID: 794443
    [No Abstract]   [Full Text] [Related]  

  • 20. Dipropylacetate-induced quasi-morphine abstinence behaviour in the rat: involvement of amygdaloid and thalamic structures.
    van der Laan JW; Bruinvels J
    Brain Res; 1981 Dec; 229(1):133-46. PubMed ID: 6272932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.